TY - JOUR
T1 - Cellular immune activity biomarker neopterin is associated hyperlipidemia
T2 - Results from a large population-based study
AU - Chuang, Shu Chun
AU - Boeing, Heiner
AU - Vollset, Stein Emil
AU - Midttun, Øivind
AU - Ueland, Per Magne
AU - Bueno-de-Mesquita, Bas
AU - Lajous, Martin
AU - Fagherazzi, Guy
AU - Boutron-Ruault, Marie Christine
AU - Kaaks, Rudolf
AU - Küehn, Tilman
AU - Pischon, Tobias
AU - Drogan, Dagmar
AU - Tjønneland, Anne
AU - Overvad, Kim
AU - Quirós, J. Ramón
AU - Agudo, Antonio
AU - Molina-Montes, Esther
AU - Dorronsoro, Miren
AU - Huerta, José María
AU - Barricarte, Aurelio
AU - Khaw, Kay Tee
AU - Wareham, Nicholas J.
AU - Travis, Ruth C.
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Trichopoulos, Dimitrios
AU - Masala, Giovanna
AU - Agnoli, Claudia
AU - Tumino, Rosario
AU - Mattiello, Amalia
AU - Peeters, Petra H.
AU - Weiderpass, Elisabete
AU - Palmqvist, Richard
AU - Ljuslinder, Ingrid
AU - Gunter, Marc
AU - Lu, Yunxia
AU - Cross, Amanda J.
AU - Riboli, Elio
AU - Vineis, Paolo
AU - Aleksandrova, Krasimira
N1 - Funding Information:
The EPIC cohort is supported by the Europe Against Cancer Program of the European Commission (SANCO). The individual centers also received funding from: Denmark: Danish Cancer Society; France: Ligue centre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM); Greece: the Hellenic Health Foundation, the Stavros Niarchos Foundation, and the Hellenic Ministry of Health and Social Solidarity; Germany : German Cancer Aid, and Federal Ministry of Education and Research; Italy: Italian Association for Research on Cancer and the National Research Council; The Netherlands: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands; Norway: Helga – Nordforsk centre of excellence in food, nutrition and health and The Norwegian Extra Foundation for Health and Rehabilitation, The Norwegian Cancer Society; Spain: Health Research Fund (FIS) of the Spanish Ministry of Health (Exp 96/0032, RETICC DR06/ 0020), the Spanish Regional Governments of Andalusia, Asturias, Basque Country, Murcia (N0 6236), and the Navarra and the Catalan Institute of Oncology; Sweden: Swedish Cancer Society, Swedish Scientific Council, and Regional Governments of Skane and Västerbotten; UK: Cancer Research UK and Medical Research Council. Grant supports for the biochemical measurements: HDL-C and TG were analysed with additional support from the Ministry of Public Health, Welfare and Sports, the Netherlands,German Cancer Aid, Federal Ministry for Education and Research, European Union, European Union and AIRC-ITALY , German Cancer Aid, Federal Ministry for Education and Research, European Union, Stavros Niarchos Foundation , Hellenic Ministry of Health, Hellenic Health Foundation, MRC and Cancer Research UK;Hba1c was analysed with additional support from National Cancer Institute grant 1RO1CA102460 and data analyses on CRP were performed with support from World Cancer Research Fund International and Wereld Kanker Onderzoek Fonds (WCRF NL). The funders played no role in designing or conducting the study or in the collection, management, analysis, and interpretation of the data, nor did they have any input into the preparation, review, or approval of this manuscript.
Publisher Copyright:
© 2016 Chuang et al.
PY - 2016/2/25
Y1 - 2016/2/25
N2 - Background: Increased serum neopterin had been described in older age two decades ago. Neopterin is a biomarker of systemic adaptive immune activation that could be potentially implicated in metabolic syndrome (MetS). Measurements of waist circumference, triglycerides, high-density lipoprotein cholesterol (HDLC), systolic and diastolic blood pressure, glycated hemoglobin as components of MetS definition, and plasma total neopterin concentrations were performed in 594 participants recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC). Results: Higher total neopterin concentrations were associated with reduced HDLC (9.7 %, p < 0.01 for men and 9.2 %, p < 0.01 for women), whereas no association was observed with the rest of the MetS components as well as with MetS overall (per 10 nmol/L: OR = 1.42, 95 % CI = 0.85-2.39 for men and OR = 1.38, 95 % CI = 0.79-2.43). Conclusions: These data suggest that high total neopterin concentrations are cross-sectionally associated with reduced HDLC, but not with overall MetS.
AB - Background: Increased serum neopterin had been described in older age two decades ago. Neopterin is a biomarker of systemic adaptive immune activation that could be potentially implicated in metabolic syndrome (MetS). Measurements of waist circumference, triglycerides, high-density lipoprotein cholesterol (HDLC), systolic and diastolic blood pressure, glycated hemoglobin as components of MetS definition, and plasma total neopterin concentrations were performed in 594 participants recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC). Results: Higher total neopterin concentrations were associated with reduced HDLC (9.7 %, p < 0.01 for men and 9.2 %, p < 0.01 for women), whereas no association was observed with the rest of the MetS components as well as with MetS overall (per 10 nmol/L: OR = 1.42, 95 % CI = 0.85-2.39 for men and OR = 1.38, 95 % CI = 0.79-2.43). Conclusions: These data suggest that high total neopterin concentrations are cross-sectionally associated with reduced HDLC, but not with overall MetS.
KW - Cell-mediated immunity
KW - Metabolic syndrome
KW - Neopterin
UR - http://www.scopus.com/inward/record.url?scp=84975682924&partnerID=8YFLogxK
U2 - 10.1186/s12979-016-0059-y
DO - 10.1186/s12979-016-0059-y
M3 - Article
AN - SCOPUS:84975682924
SN - 1742-4933
VL - 13
JO - Immunity and Ageing
JF - Immunity and Ageing
IS - 1
M1 - 5
ER -